These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35433993)

  • 1. Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report.
    Wu J; You Y; Zhuang R; Guo X; Zhang C; Zhang Q; Zhou Y; Li Q
    Ann Transl Med; 2022 Mar; 10(6):387. PubMed ID: 35433993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in
    Fang X; Mou H; Ying X; Hou X; Wang L; Wu Y; Yan N; Guo L; Liao Q
    Front Oncol; 2022; 12():1024677. PubMed ID: 36620566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian clear cell carcinoma with or without endometriosis origin in a single institution cohort.
    Sun M; Jiang W
    Discov Oncol; 2023 Apr; 14(1):39. PubMed ID: 37004660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
    Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
    Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
    [No Abstract]   [Full Text] [Related]  

  • 8. Individualize management for advanced breast cancer with pyrotinib-based anti-HER2 therapy: a case report.
    Xu J; Chen J; Huang P; Zhou H; Wang X; Chen Z
    Transl Breast Cancer Res; 2023; 4():25. PubMed ID: 38751473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study.
    Hua Y; Li W; Jin N; Cai D; Sun J; Sun C; Yang F; Wu X; Huang X; Wang B; Yin Y
    Ther Adv Med Oncol; 2022; 14():17588359221085232. PubMed ID: 35356262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-positive advanced biliary tract cancer responds to second-line pyrotinib therapy: a case report.
    Liu L; Chen Y; Zhu X; Zhao L; Chen B
    Anticancer Drugs; 2024 Mar; 35(3):298-301. PubMed ID: 38037743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological Complete Response from Pyrotinib Combined with Trastuzumab, Paclitaxel and Cisplatin in a Postpartum Woman with HER2-Positive Locally Advanced Breast Cancer: A Case Report.
    He L; Zhang F; Ma Y; Zuo L; Xu Y
    Onco Targets Ther; 2020; 13():8749-8756. PubMed ID: 32943881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors.
    Wang J; Zhang B; Cheng X; Li Q; Lv H; Nie C; Chen B; Xu W; Zhao J; He Y; Tu S; Chen X
    J Oncol; 2022; 2022():4233782. PubMed ID: 35368895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
    Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
    J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study.
    Zhang Q; He P; Tian T; Yan X; Huang J; Zhang Z; Zheng H; Zhong X; Luo T
    Front Pharmacol; 2023; 14():1100556. PubMed ID: 37025489
    [No Abstract]   [Full Text] [Related]  

  • 15. Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
    Li Y; Qiu Y; Li H; Luo T; Li W; Wang H; Shao B; Wang B; Ge R
    Front Oncol; 2021; 11():664429. PubMed ID: 33996589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant response to the combination of pyrotinib and letrozole in a patient with metastatic HER2-positive and hormone receptor-positive breast cancer: a case report.
    Li J; Shui Z; Ouyang Q
    Ann Palliat Med; 2021 Sep; 10(9):10124-10129. PubMed ID: 34628933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study.
    Zhang L; Wu X; Zhou J; Zhu M; Yu H; Zhang Y; Zhao Y; Han Z; Guo Y; Guan X; Wang X; Xu H; Sun L; Zhang J; Zhuang M; Xie L; Yu S; Chen P; Feng J
    Front Oncol; 2021; 11():699323. PubMed ID: 34336688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant pyrotinib plus trastuzumab and vinorelbine for HER2-positive locally advanced breast cancer patient who was initially resistant to HP therapy: a case report and literature review.
    Liu M; Zhou X
    Gland Surg; 2023 Feb; 12(2):317-323. PubMed ID: 36915810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of using pyrotinib combined with capecitabine as neoadjuvant therapy in elderly patients with HER2-positive breast cancer: a single-arm prospective clinical trial.
    Wang W; Zhang J; Chang JY; Yao DS; Hu F; Liang YP; Shen Y; Liu YQ; Qi HH; Tong JB; Cai HF
    Gland Surg; 2023 Feb; 12(2):208-214. PubMed ID: 36915823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report.
    Xie N; Liu L; Tian C; Hu Z; Ouyang Q
    Ann Transl Med; 2021 Aug; 9(16):1356. PubMed ID: 34532493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.